drugset / Trial / NCT03904628
Phase I Clinical Study of Oral TG02 Capsule in the Treatment of Recurrent / Progressive High-grade Glioma Patients
Non-randomizedSequentialOpen-labelTreatment
Summary
The aim of the study was to explore the dose-limiting toxicity (DLT) and the maximum tolerable dose (MTD) of oral administration of TG02 capsules twice a week for 4 weeks.
Timeline
- Start
- 2019-03-22
- Primary completion
- 2020-08-01
- Completion
- 2020-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zotiraciclib | Small molecule | 150 mg | Oral |
| Subject | Zotiraciclib | Small molecule | 200 mg | Oral |
| Subject | Zotiraciclib | Small molecule | 250 mg | Oral |